Tarceva

AZ gets rapid approval in China for Tagrisso

Moreover, nearly two thirds patients whose disease progresses after treatment with a first-line EGFR inhibitor - such as Iressa, Roche/Astellas' $2bn-a-year Tarceva (erlotinib) and Boehringer Ingelheim's Giotrif

Novocure’s chief commercial officer to step down

Previously, he was senior vice president for sales and marketing at OSI Pharmaceuticals, where he led the global commercialisation of Tarceva (erlotinib) from 2003 to 2011.

AZ's Tagrisso beats chemotherapy in lung cancer trial

The mutation develops in around two-thirds of patients who have received other EGFR inhibitors, such as Roche/Astellas' $2bn-a-year Tarceva (erlotinib), AstraZeneca's Iressa (gefitinib) and Boehringer

Reformed Cancer Drugs Fund backs its first drug - AZ’s Tagrisso

treatments, such as Roche and Astellas' Tarceva (erlotinib), AZ's Iressa (gefitinib) and Boehringer Ingelheim's Giotrif (afatinib).

Boehringer stops Gilotrif head and neck cancer trials

It is already vying in the marketplace against AstraZeneca's Iressa (gefitinib) and Roche/Astellas' Tarceva (erlotinib) in first-line NSCLC, and looks likely to face increased pressure with the availability

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]